Cytosine arabinoside therapy for acute myeloid leukaemia in adults.
D000005:Abdomen / Q000187:drug effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D001855:Bone Marrow Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D014456:Ulcer / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003561:Cytarabine